• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    10/30/23 1:55:55 PM ET
    $ACLS
    $ADD
    $AEHR
    $ALGN
    Industrial Machinery/Components
    Technology
    Engineering & Construction
    Consumer Discretionary
    Get the next $ACLS alert in real time by email

    Gainers

    • Miromatrix Medical Inc. (NASDAQ:MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
    • Eargo, Inc. (NASDAQ:EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital.
    • VYNE Therapeutics Inc. (NASDAQ:VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.
    • Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday.
    • HeartCore Enterprises, Inc. (NASDAQ:HTCR) surged 24% to $0.7718. Heartcore Enterprises recently entered into at-market offering agreement for an at-market offering with H.C. Wainwright & Co.
    • ImmunityBio, Inc. (NASDAQ:IBRX) gained 19.4% to $2.9600. The FDA recently accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.
    • Coherus BioSciences, Inc. (NASDAQ:CHRS) shares climbed 16.8% to $3.0850. Coherus and Junshi Biosciences reported FDA approval of LOQTORZI in all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma.
    • Aemetis, Inc. (NASDAQ:AMTX) gained 16.5% to $5.02. Aemetis received $150 million biodiesel supply allocation from India oil marketing companies.
    • JinkoSolar Holding Co., Ltd. (NYSE:JKS) surged 16% to $30.01 following better-than-expected quarterly results.
    • Akerna Corp. (NASDAQ:KERN) jumped 16% to $0.3550.
    • MeiraGTx Holdings plc (NASDAQ:MGTX) rose 16% to $4.29. MeiraGTx announced a $30 million strategic investment from Sanofi via purchase of 4 million shares at $7.50 per share.
    • Motus GI Holdings, Inc. (NASDAQ:MOTS) rose 15.6% to $0.4742 after declining 11% on Friday. The company recently received FDA clearance to commercialize Pure-Vu EVS Gastro and Gen 4 Colon.
    • Global Mofy Metaverse Limited (NASDAQ:GMM) jumped 15.4% to $12.10.
    • My Size, Inc. (NASDAQ:MYSZ) shares gained 15.1% to $0.8059.
    • Daqo New Energy Corp. (NYSE:DQ) gained 15% to $26.82 following quarterly results.
    • Save Foods, Inc. (NASDAQ:SVFD) rose 14.8% to $2.3369.
    • Lumentum Holdings Inc. (NASDAQ:LITE) gained 13.3% to $40.85.
    • Safety Shot, Inc. (NASDAQ:SHOT) rose 12.8% to $1.32. The company announced the direct-to-consumer launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, in the first week of Dec. 2023.
    • XPO, Inc. (NYSE:XPO) gained 12.2% to $75.54 after the company reported better-than-expected third-quarter financial results.
    • HUTCHMED (China) Limited (NASDAQ:HCM) surged 12.2% to $20.73.
    • BeiGene, Ltd. (NASDAQ:BGNE) gained 11.2% to $189.60. BeiGene recently said BRUKINSA received a positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukemia.
    • Western Digital Corporation (NASDAQ:WDC) climbed 10.3% to $42.99 after the company reported first-quarter results and announced a plan to separate its HDD and Flash businesses.
    • Color Star Technology Co., Ltd. (NASDAQ:ADD) surged 9% to $0.2845.
    • Intuitive Machines, Inc. (NASDAQ:LUNR) gained 6.2% to $2.8350 as the company said that in coordination with SpaceX, liftoff of the IM-1 lunar mission is now targeted for a multi-day launch window which opens Jan. 12, 2024.

    Losers

    • CommScope Holding Company, Inc. (NASDAQ:COMM) shares fell 32.2% to $1.64 after the company reported preliminary third-quarter financial results.
    • LumiraDx Limited (NASDAQ:LMDX) declined 30.5% to $0.0833. On Oct. 24, LumiraDx announced receipt of Nasdaq delisting determination.
    • Alzamend Neuro, Inc. (NASDAQ:ALZN) fell 30.1% to $0.1216 after the company announced a reverse stock split.
    • Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ:BHAT) fell 23.4% to $1.24.
    • Aehr Test Systems (NASDAQ:AEHR) declined 23.5% to $22.80.
    • Tenax Therapeutics, Inc. (NASDAQ:TENX) fell 21.9% to $0.1975.
    • Biophytis (NASDAQ:BKYI) dipped 20.2% to $0.1755 after jumping over 28% on Friday. BIO-Key International recently posted a narrower quarterly loss.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) fell 18.5% to $0.1511.
    • ON Semiconductor Corporation (NASDAQ:ON) fell 18.4% to $68.14 after the company reported third-quarter financial results and issued fourth-quarter adjusted EPS and revenue guidance below estimates.
    • Revvity, Inc. (NYSE:RVTY) declined 18.2% to $80.00 after the company reported worse-than-expected third-quarter results lowered its FY23 guidance.
    • Forbion European Acquisition Corp. (NASDAQ:FRBN) fell 15.5% to $24.01.
    • Aptose Biosciences Inc. (NASDAQ:APTO) dipped 14.2% to $2.7450.
    • Seelos Therapeutics, Inc. (NASDAQ:SEEL) fell 13.9% to $0.1781.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) declined 13.8% to $0.8792.
    • Nuvve Holding Corp. (NASDAQ:NVVE) shares fell 12.7% to $0.1876 after declining over 8% on Friday. Nuvve recently announced pricing of a $2.066 million registered direct offering priced at-the-market.
    • Marine Products Corporation (NYSE:MPX) declined 11% to $9.91. Marine Products recently reported worse-than-expected third-quarter financial results.
    • Axcelis Technologies, Inc. (NASDAQ:ACLS) fell 10.4% to $123.70.
    • Fisker Inc. (NYSE:FSR) fell 10.1% to $4.3050.
    • MingZhu Logistics Holdings Limited (NASDAQ:YGMZ) shares fell 9.2% to $0.54.
    • Align Technology, Inc. (NASDAQ:ALGN) fell 7% to $177.59.
    • Dana Incorporated (NYSE:DAN) declined 6.3% to $11.83.
    • NXP Semiconductors N.V. (NASDAQ:NXPI) fell 6.2% to $168.10.

    Now Read This: Microsoft, V.F. Corp And More: CNBC's 'Final Trades'

    Get the next $ACLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLS
    $ADD
    $AEHR
    $ALGN

    CompanyDatePrice TargetRatingAnalyst
    ON Semiconductor Corporation
    $ON
    2/12/2026$75.00Equal Weight
    Barclays
    XPO Inc.
    $XPO
    2/11/2026$210.00Positive → Neutral
    Susquehanna
    ON Semiconductor Corporation
    $ON
    2/10/2026Buy → Hold
    The Benchmark Company
    Align Technology Inc.
    $ALGN
    2/9/2026$200.00Hold → Buy
    HSBC Securities
    Western Digital Corporation
    $WDC
    1/30/2026$200.00 → $325.00Buy
    TD Cowen
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    ON Semiconductor Corporation
    $ON
    1/22/2026$62.00Underperform → Neutral
    BNP Paribas Exane
    XPO Inc.
    $XPO
    1/13/2026$148.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $ACLS
    $ADD
    $AEHR
    $ALGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 25, 2026 /CNW/ -- Equity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), CRISPR Therapeutics (NASDAQ:CRSP), BioNTech (NASDAQ:BNTX), and Novocure (NASDAQ:NVCR). The broader oncology market is projected to nearly triple from $279.98 bill

    2/25/26 9:00:00 AM ET
    $BNTX
    $CRSP
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Intuitive Machines Advancing Satellite Communications and In-Space Data Processing Capabilities with $175 Million Strategic Investment

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (NASDAQ:LUNR) ("Intuitive Machines" or the "Company"), a leading space infrastructure and services company, today announced a $175 million strategic equity investment led by global institutional investors. Following its acquisition of Lanteris Space Systems ("Lanteris") in January, the Company intends to use this capital to support revenue expansion and investment in technologies to advance communications and data processing networks, including extending flight-proven satellite platforms into those growth markets.  Intuitive Machines intends to invest in expanding its Near Space Network Services ("NSNS") and establish a

    2/25/26 8:30:00 AM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    Intuitive Machines Announces Date for Fourth Quarter, Full-Year 2025 Financial Results, and Post-Lanteris Space Systems Acquisition Conference Call

    HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (NASDAQ:LUNR) ("Intuitive Machines") ("Company") announced today that it will release its financial results for the fourth quarter and full-year of 2025 on Thursday, March 19, 2026, before the market opens. Following the news release, the Company will host a conference call the same day at 8:30 am ET to discuss the results as well as growth opportunities following the Lanteris Space Systems acquisition. To participate in the call, please dial (800) 715-9871 (USA & Canada) or (646) 307-1963 (International) and reference Conference ID 2767132. A webcast replay will be available on the investors portion of the Intuitive Mac

    2/24/26 10:27:48 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on onsemi with a new price target

    Barclays initiated coverage of onsemi with a rating of Equal Weight and set a new price target of $75.00

    2/12/26 9:42:14 AM ET
    $ON
    Semiconductors
    Technology

    XPO, Inc. downgraded by Susquehanna with a new price target

    Susquehanna downgraded XPO, Inc. from Positive to Neutral and set a new price target of $210.00

    2/11/26 7:51:34 AM ET
    $XPO
    Transportation Services
    Consumer Discretionary

    onsemi downgraded by The Benchmark Company

    The Benchmark Company downgraded onsemi from Buy to Hold

    2/10/26 7:17:53 AM ET
    $ON
    Semiconductors
    Technology

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Luzon Ronen bought $2,925 worth of shares (3,750 units at $0.78), increasing direct ownership by 1% to 293,085 units (SEC Form 4)

    4 - My Size, Inc. (0001211805) (Issuer)

    12/30/25 10:05:50 AM ET
    $MYSZ
    Computer Software: Prepackaged Software
    Technology

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Selecky Christobel exercised 25,000 shares at a strike of $2.98 and sold $250,000 worth of shares (25,000 units at $10.00) (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:58 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Soon-Shiong Patrick converted options into 114,329 shares and covered exercise/tax liability with 58,170 shares, increasing direct ownership by 0.19% to 29,757,911 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:07 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Sachs David C. converted options into 40,650 shares and covered exercise/tax liability with 20,682 shares, increasing direct ownership by 7% to 300,143 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:12 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLS
    $ADD
    $AEHR
    $ALGN
    SEC Filings

    View All

    Intuitive Machines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - Intuitive Machines, Inc. (0001844452) (Filer)

    2/25/26 8:49:24 AM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    CDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - CDT Equity Inc. (0001896212) (Filer)

    2/24/26 5:11:37 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by CDT Equity Inc.

    PRE 14A - CDT Equity Inc. (0001896212) (Filer)

    2/24/26 4:53:07 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Leadership Updates

    Live Leadership Updates

    View All

    Dana Incorporated Announces Appointment of Byron Foster as Chief Executive Officer

    MAUMEE, Ohio, Feb. 12, 2026 /PRNewswire/ -- Dana Incorporated (NYSE:DAN) today announced that its board of directors has appointed Byron Foster as Chief Executive Officer, effective July 1, 2026. This planned effective date allows for a structured transition period. R. Bruce McDonald, who has served as Chairman and CEO since 2024, will continue in his role as Chairman of the Board. Mr. Foster currently serves as Senior Vice President and President of Light Vehicle Systems, Dana's largest business unit. He joined Dana in 2021 to lead the company's global commercial, marketing,

    2/12/26 6:59:00 AM ET
    $DAN
    Auto Parts:O.E.M.
    Consumer Discretionary

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Financials

    Live finance-specific insights

    View All

    Intuitive Machines Announces Date for Fourth Quarter, Full-Year 2025 Financial Results, and Post-Lanteris Space Systems Acquisition Conference Call

    HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (NASDAQ:LUNR) ("Intuitive Machines") ("Company") announced today that it will release its financial results for the fourth quarter and full-year of 2025 on Thursday, March 19, 2026, before the market opens. Following the news release, the Company will host a conference call the same day at 8:30 am ET to discuss the results as well as growth opportunities following the Lanteris Space Systems acquisition. To participate in the call, please dial (800) 715-9871 (USA & Canada) or (646) 307-1963 (International) and reference Conference ID 2767132. A webcast replay will be available on the investors portion of the Intuitive Mac

    2/24/26 10:27:48 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dana Incorporated Reports Strong 2025 Financial Results; Reaffirms 2026 Targets Featuring New Business Growth, Increased Margins

    2025 Highlights:Sales of $7.5 billionAdjusted EBITDA of $610 million; $10 million higher than preliminary estimate8.1 percent adjusted EBITDA margin; 10 basis points higher than preliminary estimateAdjusted free cash flow of $331 million; $16 million higher than preliminary estimateCompleted sale of the Off‑Highway businessAchieved $248 million in cost savings; in line with our preliminary estimateReturned $704 million to shareholdersRepurchased 34 million shares, representing 23% of shares outstanding2026 Highlights:Completed nearly $2 billion in debt reduction, supported by proceeds from the Off‑Highway saleAnnounced capital return program has been extended and increased from $1 billion to

    2/18/26 6:59:00 AM ET
    $DAN
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ACLS
    $ADD
    $AEHR
    $ALGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/4/24 4:05:33 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care